Yi Ba

Harbin Medical University — China

Medicine · Health Sciences

60h-index21.7kcitations390works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(102), Colorectal Cancer Treatments and Studies(69), MicroRNA in disease regulation(60), Circular RNAs in diseases(43), Cancer-related molecular mechanisms research(41)

Publications388 total

Probabilistic Fatigue Life Evaluation of Wire Ropes in Port Systems: An Integrated FEM and Non-Dimensional Interference Model
Journal of Physics Conference Series·2025Open Access
Effectiveness of sensory integration-based intervention in autistic children, focusing on Chinese children: a systematic review and meta-analysis
Frontiers in Psychiatry·2025Open Access
Clinical trial design in rare mutation tumors
Holistic Integrative Oncology·2025Open Access
Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study
Blood·2025
Pharmacokinetic failure of obinutuzumab due to massive third-space sequestration in a patient with high-burden follicular lymphoma: A rationale for therapeutic drug monitoring and dose intensification
Blood·2025
Progress and Challenges in Brain-Computer Interface-Based Hand Rehabilitation Robots
Theoretical and Natural Science·2025Open Access
Preparation of barium ferrite nanoparticles by crystallization from amorphous precursors and their crystallization kinetics
Ceramics International·2025
Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors—A phase 1/1b study
Cell Reports Medicine·2025Open Access
Safety of Recombinant von Willebrand Factor in the Treatment of von Willebrand Disease: Real-World Data from an EU Post-Authorization Safety Study
Journal of Blood Medicine·2025Open Access
An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study
Cancer Letters·2025
Breakthrough therapy designations in China and the United States
Nature Reviews Drug Discovery·2025· 1 cited
From Theory to Practice
American Journal Of Pathology·2025· 1 cited
2098MO Cadonilimab (Cado) plus chemotherapy (chemo) versus chemotherapy as first-line (1L) treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Final results of the phase III COMPASSION-15 trial
Annals of Oncology·2025
Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach
Cancer Medicine·2025· 1 citedOpen Access
Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial
Cancer·2025Open Access
Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis
Cancer and Metastasis Reviews·2025
A phase prediction strategy of high entropy alloys manufactured by selective laser melting based on feature selection and machine learning
Journal of Materials Research and Technology·2025· 4 citedOpen Access
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Journal of Clinical Oncology·2025· 8 citedOpen Access
Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial.
Journal of Clinical Oncology·2025
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial
Signal Transduction and Targeted Therapy·2025· 5 citedOpen Access
page 1 of 20Next →

Frequent Co-authors

Ting Deng(24), Haiyang Zhang(21), Guoguang Ying(16), Jialu Li(11), Tao Ning(11), Haiou Yang(10), Rui‐Hua Xu(10), Shaohua Ge(9), Qian Fan(9), Kegan Zhu(9), Ke Zen(8), Ming Bai(8), Hongli Li(8), Tao Ning(7), Yuxian Bai(7), Wu Sun(7), Xi Chen(6), Chen-Yu Zhang(6), Qingxia Fan(6), Xinyi Wang(6)